Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.

ABSTRACT:

Background

Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited.

Methods

In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies against CD166 was performed on different cell samples. CD166-specific T cells were obtained by viral gene transfer of corresponding DNA plasmids and selectively expanded using IL-2 and IL-15. The ability of CD166.BBζ CAR-T cells to kill CD166⁺ osteosarcoma cells was evaluated in vitro and in vivo.

Results

CD166 was selectively expressed on four different human osteosarcoma cell lines, indicating its role as the novel target for C

SUBMITTER: Wang Y 

PROVIDER: S-EPMC6471997 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature